Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Dx Firm Nucleix Raises $3M

NEW YORK (GenomeWeb) – Israeli epigenetics-based diagnostics firm Nucleix announced today that it has completed a $3 million private financing round. 

Nucleix said that the proceeds of the round will be used to complete the clinical studies required for US Food and Drug Administration approval of its urine-based bladder cancer test Bladder EpiCheck, and to begin marketing efforts for the test in Europe. The company also said that it would use the money to expand its 16-employee workforce.

The round was led by Aurum Ventures MKI and existing shareholder Zohar Zisapel, and comes roughly two years after Nucleix closed a $5 million round of financing. Since its founding in 2008, the firm has raised over $13 million.